<DOC>
	<DOCNO>NCT00498836</DOCNO>
	<brief_summary>Patients metastatic malignant melanoma receive CP-4055 200 mg/m2/day intravenously ( IV ) Day 1-5 every four week sorafenib 400 mg b.i.d . ( twice daily ) every day complete response disease worsening/progressing .</brief_summary>
	<brief_title>Multicentre , Dose Finding , Ph II , CP-4055 Comb . With Sorafenib - Patients With Metastatic Malignant Melanoma</brief_title>
	<detailed_description>This multicentre clinical study conduct USA Europe . It open label study design investigate objective tumor response , time progression ( TTP ) duration tumor response patient metastatic malignant melanoma treat CP-4055 combination sorafenib ( NexavarÂ® ) . The safety tolerability treatment also assess .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients histological cytological confirm stage IV unresectable stage III nonocular malignant melanoma undergone prior chemotherapy treatment melanoma 2 . Measurable disease accord Response Criteria In Solid Tumors ( RECIST ) 3 . Performance Status 0 1 accord ECOG ( Eastern Cooperative Oncology Group ) Performance Status 4 . Age 18 year 5 . Life expectancy &gt; 3 month 6 . Signed informed consent 7 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must negative serum urine pregnancy test within 2 week prior begin treatment study 8 . Male female patient must use acceptable contraceptive method duration time study , male also 3 month last CP4055 dose 9 . Adequate haematological biological function 1 . Known brain metastasis 2 . Diagnosis ocular malignant melanoma 3 . Radiotherapy 30 % bone marrow 4 . Participation another therapeutic clinical study within 30 day enrolment clinical study 5 . Requirement concomitant treatment nonpermitted medication : Alternative drug High dos vitamins 6 . History allergic reaction araC egg 7 . History allergic reaction attribute compound similar chemical biological composition sorafenib 8 . Presence serious concomitant systemic disorder incompatible clinical study ( e.g . uncontrolled intercurrent illness include ongoing active infection ) 9 . Presence significant central nervous system psychiatric disorder ( ) would hamper patient 's compliance 10 . Pregnancy , breastfeed absence adequate contraception male female fertile patient 11 . Known positive status HIV and/or hepatitis B C 12 . Drug and/or alcohol abuse 13 . Any reason , investigator 's opinion , patient participate 14 . Prior treatment CP4055 and/or sorafenib 15 . Significant history cardiac disease , include follow : Uncontrolled hypertension Unstable angina pectoris Congestive heart failure Myocardial infarction within past 6 month Unstable ventricular arrhythmia Other cardiac arrhythmia 16 . Condition impair ability swallow pill 17 . Tendency bleed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>CP-4055</keyword>
	<keyword>Elacyt</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Malignant melanoma</keyword>
	<keyword>Combination treatment</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
</DOC>